Sign in
CompletedNo phase

Characterization and Modulation of Traumatic Memories in PTSD Patients Using TMS

Key facts

Who runs it
Tel Aviv University
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
10 people enrolled
Started
23 Feb 2022
Ended
24 Oct 2024
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Trans-Cranial Magnetic Stimulation
Record updated
1 November 2024

Who can take part

Age
20 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adults aged 20-65 of both sexes, who meet the diagnosis of PTSD according to DSM-5 as tested by a structured clinical interview (Clinician-Administered PTSD Scale - CAPS-5). The clinical interview will be performed by clinical psychologists
  • CAPS-5 (Clinician-Administered PTSD Scale) score higher than 33
  • Subjects who experience intrusive symptoms (flashbacks, nightmares, or intrusive memories) at least 4 times a week
  • Only subjects with a level of Hebrew that allows a full understanding of the consent form to participate in the experiment will be included in the experiment
  • In addition, the accepted criteria for inclusion for an MRI examination for medical purposes will be applied, according to the established procedures at the MRI Institute at the Sourasky Tel Aviv Medical Center and at the Imaging Center at Tel Aviv University

Who cannot take part

  • Use of the following drugs:; The list of drugs that constitute a criterion for exclusion in the study: imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma- hydroxybutyrate (GHB), alcohol, theophylline
  • Victims with traumatic head injuries or who have undergone head surgery
  • Subjects who use drugs
  • Subjects who have previously experienced repeated episodes of fainting with loss of consciousness and/or an event of fainting with loss of consciousness in the past year. (reaction and vegalit)
  • Subjects who meet the diagnosis of Complex PTSD or personality disorder
  • Subjects who suffer or have suffered in the past from a psychotic disorder, bipolar disorder, or a developmental neuropsychological disorder (autism, mental retardation)
  • Use of psychiatric medications (except for the medications listed in section 4.a) will not be an expense criterion if the medication dosage is stable in the last three months and does not change during the study; In addition, exclusion criteria 4-13 will apply according to the exclusion rules in TMS laboratories in England and the USA:
  • Subjects suffering from epilepsy or taking anti-epileptic drugs
  • Having a metallic body (except fillings/amalgam bites/orthodontic fixations approved for MRI), electrodes or a pacemaker in their body
  • Subjects suffering from migraines
  • Pregnant women
  • Subjects with hearing problems
  • Subjects who drank alcohol 24 hours before the experiment
  • In addition, the accepted exclusion criteria for an MRI examination for medical purposes will apply, according to the established procedures at the MRI Institute at the Sourasky Tel Aviv Medical Center and at the Imaging Center at Tel Aviv University

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Characterization and modulation of traumatic memories in PTSD patients using TMS.

The 2 groups in the trial

  • Hippocampus StimulationTreatment being tested

    Treatment: Trans-Cranial Magnetic Stimulation

  • Sham StimulationSham treatment, for comparison

    Treatment: Trans-Cranial Magnetic Stimulation

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
1 November 2024